Dr. Slawin’s industry keynote address, “Building on the Foundation of Four: Advancing Mitochondrial‑Targeted Geropeptide Medicine” will directly follow Dr. Hazel H. Szeto’s historic academic keynote address, “From Mitochondrial Discovery to Approved Therapy: Lessons for the Future of Medicine” that is scheduled to open the conference.
